SGLT2 inhibitors: The science behind multi-organ benefits; What’s next?

AstraZeneca |

Chair: Hiddo Lambers Heerspink (NLD)

15:30 – 15:35Chair welcome and introductionsHiddo Lambers Heerspink (NLD)
15:35 – 15:55Cellular energetics and the positive impact of SGLT2 inhibitionEsther Phielix (NLD)
15:55 – 16:15The science supporting SGLT2 inhibitors renal benefitsHiddo Lambers Heerspink (NLD)
16:15 – 16:35The underlying mechanisms of SGLT2 inhibitors across the ejection fraction spectrumKieran Docherty (UK)
16:35 – 16:55SGLT2 inhibitors: Where do we go from here?All faculty
16:55 – 17:00Summary and closeHiddo Lambers Heerspink (NLD)

Disclaimer: This non-promotional symposium is organized and funded by AstraZeneca for healthcare professionals only.